Symbols

IBRX

ImmunityBio·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 6

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

Revenue Beats Expectation

EPS Beats Expectation

FDA Approved

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IBRX

Immunitybio, Inc.

A clinical-stage biotech company developing novel immunotherapies for cancer and infectious diseases

Industry

Pharmaceutical

Established Date

10/07/2002

Listing Date

07/28/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

680

Fiscal Year Ends

12-31

Website

www.immunitybio.com

Security Type

Common stock

Office address

3530 John Hopkins Court, San Diego, California 92121

Business

Introduction

ImmunityBio, Inc., was incorporated on October 7, 2002 under the name of ZelleRx Corporation, Illinois, and on January 22, 2010, the company changed its name to Conkwest Co., Ltd. ImmunityBio is a leading late-stage immunotherapy company that activates the innate and adaptive immune systems to treat serious unmet needs in oncology and infectious diseases. The company is a leading manufacturer of ready-made natural killer cell therapies in clinical formulations, a comprehensive platform for memory NK cells, along with antibody cytokine fusion proteins, albumin-binding chemical immunomodulators and vaccine vectors. By combining these NK, macrophage and T-cell activation platforms, the company believes that ImmunityBio is a leader in immunotherapy with late-stage clinical development across multiple tumor types and infectious diseases.

Company Financials

EPS

IBRX has released its 2025 Q3 earnings. EPS was reported at -0.07, versus the expected -0.1, beating expectations. The chart below visualizes how IBRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IBRX has released its 2025 Q3 earnings report, with revenue of 32.06M, reflecting a YoY change of 425.07%, and net profit of -67.27M, showing a YoY change of 21.55%. The Sankey diagram below clearly presents IBRX's revenue sources and cost distribution.